Showing results (431-440 of 443) with videos related to

Sort By:
Pageof 45
Cell|May 3, 2016
Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in HumansTommi Vatanen, Aleksandar D Kostic, Eva d'Hennezel, et al.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Annals of Medicine|April 24, 2015
Helsinki alert of biodiversity and healthLeena von Hertzen, Bruce Beutler, John Bienenstock, et al.
Nature Microbiology|December 19, 2018
Genomic variation and strain-specific functional adaptation in the human gut microbiome during early lifeTommi Vatanen, Damian R Plichta, Juhi Somani, et al.
Nature Microbiology|February 7, 2019
Publisher Correction: Genomic variation and strain-specific functional adaptation in the human gut microbiome during early lifeTommi Vatanen, Damian R Plichta, Juhi Somani, et al.
Nature Communications|December 3, 2025
Microbiome-derived bile acid signatures in early life and their association with islet autoimmunitySantosh Lamichhane, Alex M Dickens, Tanja Buchacher, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2025
Trajectories of microbiome-derived bile acids in early life - insights into the progression to islet autoimmunitySantosh Lamichhane, Alex M Dickens, Tanja Buchacher, et al.
JAMA|January 4, 2018
Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial, Mikael Knip, Hans K Åkerblom, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Diabetes/Metabolism Research and Reviews|July 4, 2024
Multi-omics analysis reveals drivers of loss of β-cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter studyJose Juan Almagro Armenteros, Caroline Brorsson, Christian Holm Johansen, et al.
Pageof 45